87 / 464
SATURDAY 6 MAY 2017
INTERDISCIPLINARY RADIOBIOLOGY CLINICAL BRACHYTHERAPY PHYSICS RTT YOUNG
87
Programme and Exhibition Guide |
SCIENTIFIC PROGRAMME
SYMPOSIUM
The optimal approach to treat oligometastastic disease: different ways
to handle an indication quickly gaining acceptance
14:45 - 16:00 | AUDITORIUM
Radical radiotherapy in the form of stereotactic body radiotherapy (SBRT) has become
a routine practice in many institutions for patients with oligo-metastatic disease. This
rapid development was observed despite the lack prospective evidence proofing the
value of SBRT, despite oligo-oligometastasis is poorly defined and despite patient
selection criteria are still limited. This symposium summarises the challenges of the
oligo-metastatic concept, the role of radiotherapy and surgery and appropriate patient
selection for these local treatment options. A clinical approach to the abscopal effect –
investigated in many pre-clinical studies but observed rarely in daily clinical practice
– is presented and discussed.
Chair: M. Guckenberger (Switzerland)
Co-chair: I. Ratosa (Slovenia)
14:45 > Clinical approach to abscopal effects
Speaker: P.C. Lara Jimenez (Spain)
SP-0097
15:03 > What is the purpose of surgical metastasectomy and do we achieve it?
Speaker: T. Treasure (UK)
SP-0098
15:21 > What is the indication and what is the aim of clinical treatment:
radiotherapy
Speaker: E. Lartigau (France)
SP-0099
15:39 > Oligometastastic cancer: a therapeutic challenge
Speaker: K. Van der Hoeven (The Netherlands)
SP-0100
SYMPOSIUMWITH PROFFERED PAPERS
Targeting tumour heterogeneity
14:45 - 16:00 | SCHUBERT
It is well known that a tumour is not a homogeneous collection of malignant cells. In
contrast to that a tumour lump consist of e.g. areas with cells of different differentiation
grade and different oxygenation caused by development of multiple subclones at the
same time. These subclones are often spatially segregated. An example is prostate
cancer with areas of different Gleason patterns and oxygenation as has been shown by
BOLD-MRI. Focal treatment of prostate cancer has evolved to treat only the dominant
intraprostatic lesion(s) leaving out non-significant disease. One reason to differentiate
treatment between areas of the same tumour is that genotypes and phenotypes that
evolve often differ between primary tumours and metastases. The resulting subclonal
heterogeneity complicates effective targeting. New challenges are arising for targeting